Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
WOS: 000338633500034
PubMed ID: 24870753
Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to prese
PubMed ID: 24870753
Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to prese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd7f7d2e9061bbc1a8fbe942af030249
http://hdl.handle.net/11655/20788
http://hdl.handle.net/11655/20788
Autor:
Ozgur Tanriverdi, Serkan Menekse, Faysal Dane, Mukremin Uysal, Metin Ozkan, Halit Karaca, Mehmet Besiroglu, Ibrahim Vedat Bayoglu, Ayse Ocak Duran, Dogan Yazilitas, Alper Sevinc, Ilhan Hacibekiroglu, Erkan Arpaci, Aykut Bahceci, Mevlude Inanc, Heves Surmeli Yapici, Asude Aksoy
WOS: 000351058400056
PubMed ID: 25556478
Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this s
PubMed ID: 25556478
Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4644b7109f838e680f4e4429b7551933
https://hdl.handle.net/20.500.12809/3548
https://hdl.handle.net/20.500.12809/3548
Autor:
Mahmut Gumus, Necati Alkis, Bilge Aktas, Mevlude Inanc, Fatma Tugba Kos, Umut Demirci, Özlem Sönmez, Erdogan Selcuk Seber, Suleyman Alici, Tarkan Yetisyigit, Ramazan Yildiz, Mehmet Kucukoner, Tulay Akman, Erkan Arpaci, Yusuf Gunaydin
Background: We aimed to evaluate prognostic factors and response rates to various treatment approaches to patients with synovial sarcoma in an advanced setting. Materials and Methods: We retrospectively reviewed the medical records of 55 patients (18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f77d635cbb587c2c7ecffd1140bf1de
https://hdl.handle.net/20.500.11776/8970
https://hdl.handle.net/20.500.11776/8970
WOS: 000328271800037
PubMed ID: 24083725
Background: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its exp
PubMed ID: 24083725
Background: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c93b73b953749ea5db07699603374f6
https://hdl.handle.net/11454/47957
https://hdl.handle.net/11454/47957